RF
BCRX icon

RHS Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

RHS Financial’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$149K Sell
17,832
-1,186
-6% -$11.2K 0.05% 184
2026
Q2 		$190K Buy
+19,018
New +$172K 0.08% 162

Other funds holding BCRX

WCM
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
MBI
May Barnhard Investments Bethesda, Maryland $243M AUM 13.89% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $552M AUM 32.44% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

RHS Financial's BCRX Position: Q3 2026 in Review

RHS Financial reduced its BioCryst Pharmaceuticals (BCRX) stake by 6.2% in Q3 2026, selling an estimated $11.2K and leaving 17,832 shares worth $149K. The position accounts for 0.05% of the portfolio, ranked #184.

RHS Financial first reported a position in BCRX in Q2 2026 and has held it in 2 quarters since. The position peaked at $190K in Q2 2026. 11 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • RHS Financial held 17,832 shares of BioCryst Pharmaceuticals worth $149K as of Q3 2026.
  • RHS Financial sold 1,186 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $11.2K.
  • BioCryst Pharmaceuticals made up 0.05% of RHS Financial's portfolio in Q3 2026, its #184 holding.
  • RHS Financial first reported a position in BioCryst Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • RHS Financial's BioCryst Pharmaceuticals position peaked at $190K in Q2 2026.
  • 11 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on RHS Financial's 13F filing for Q3 2026, filed 13 Oct 2026.